ERBB2 and esophageal cancer: Moreover, enrichment of FYN has also been observed in residual disease following chemotherapy, including neoadjuvant chemostherapy plus bevacizumab-treated HER2 negative breast cancer (Kimbung et al., 2018), neoadjuvant chemoradiotherapy combined plus atezolizumab-treated esophageal cancer (van den Ende et al., 2021), and chemoradiotherapy-treated colorectal cancer (Snipstad et al., 2010), indicating its potential role in mediating drug tolerance during chemotherapy (Figure 5I).